Compare · AVTR vs LAB
AVTR vs LAB
Side-by-side comparison of Avantor Inc. (AVTR) and Standard BioTools Inc. (LAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and LAB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $9.75B, about 38.2x LAB ($255.2M).
- Over the past year, AVTR is up 8.5% and LAB is down 49.6% - AVTR leads by 58.1 points.
- LAB has been more active in the news (9 items in the past 4 weeks vs 3 for AVTR).
- AVTR has more recent analyst coverage (25 ratings vs 5 for LAB).
- Company
- Avantor Inc.
- Standard BioTools Inc.
- Price
- $14.41+1.02%
- $0.65-0.08%
- Market cap
- $9.75B
- $255.2M
- 1M return
- +22.53%
- -15.85%
- 1Y return
- +8.47%
- -49.61%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2011
- News (4w)
- 3
- 9
- Recent ratings
- 25
- 5
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Latest AVTR
- President and CEO Ligner Emmanuel covered exercise/tax liability with 29,803 shares, decreasing direct ownership by 4% to 737,334 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.07% to 248,864 units (SEC Form 4) (withholding tax)
- SVP & Chief Accounting Officer Eck Steven W covered exercise/tax liability with 1,385 shares, decreasing direct ownership by 1% to 129,593 units (SEC Form 4) to satisfy withholding tax
- Avantor upgraded by Jefferies with a new price target
- SEC Form 10-Q filed by Avantor Inc.
- Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Avantor® Reports Second Quarter 2026 Results
- EVP, Chief Legal & Compliance Sokenu Claudius covered exercise/tax liability with 1,201 shares, decreasing direct ownership by 0.48% to 251,228 units (SEC Form 4) to cover withholding tax
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
Latest LAB
- SVP & Chief Business Officer Mackay Sean covered exercise/tax liability with 25,729 shares, decreasing direct ownership by 2% to 1,480,823 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Kim Hanjoon Alex covered exercise/tax liability with 28,195 shares, decreasing direct ownership by 1% to 2,534,859 units (SEC Form 4) (for withholding tax)
- President & CEO Egholm Michael covered exercise/tax liability with 97,627 shares, decreasing direct ownership by 2% to 6,137,704 units (SEC Form 4) (for tax liability)
- SEC Form S-8 filed by Standard BioTools Inc.
- SEC Form S-8 filed by Standard BioTools Inc.
- SEC Form 10-Q filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Standard BioTools Reports Second Quarter 2026 Financial Results
- President & CEO Egholm Michael covered exercise/tax liability with 362,625 shares, decreasing direct ownership by 5% to 6,235,331 units (SEC Form 4) (tax withholding)
- SEC Form 425 filed by Standard BioTools Inc.